B J Weigel

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
    B J Weigel
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    J Pediatr Hematol Oncol 23:272-6. 2001
  2. ncbi Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
  3. ncbi In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
    A B Pawlowska
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 97:1474-82. 2001
  4. ncbi Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors
    C J Fraser
    Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 37:175-81. 2006

Collaborators

Detail Information

Publications4

  1. ncbi Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
    B J Weigel
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    J Pediatr Hematol Oncol 23:272-6. 2001
    ..This review summarizes the published data on the use of high-dose chemotherapy and hematopoietic stem cell rescue (HSCR) in the treatment of recurrent or metastatic rhabdomyosarcoma (RMS)...
  2. ncbi Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
    ..These data have important clinical implications and are the first to show that Flt3L-generated DCs can provide antitumor protection and that nontoxic agents such as CpGs and Flt3L may be useful in the clinical development of DC vaccines...
  3. ncbi In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
    A B Pawlowska
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 97:1474-82. 2001
    ..It was concluded that DC vaccines and Flt3L administration can enhance an AML response in non-transplanted or syngeneic BMT mice but only when initiated prior to AML progression...
  4. ncbi Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors
    C J Fraser
    Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 37:175-81. 2006
    ..Median follow-up among survivors is 3.5 years (range: 0.6-7.9 years). These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT...